P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy

類似資料

• Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
  著者:: Piha-Paul, Sarina A., 等
  出版事項: (2014)
• A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer
  著者:: Falchook, Gerald S., 等
  出版事項: (2014)
• Xilonix, a Novel True Human Antibody Targeting the Inflammatory Cytokine Interleukin-1 alpha, in Non-Small Cell Lung Cancer
  著者:: Hong, David S., 等
  出版事項: (2015)
• PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials
  著者:: Janku, Filip, 等
  出版事項: (2012)
• Characteristics and survival of patients with advanced cancer and p53 mutations
  著者:: Said, Rabih, 等
  出版事項: (2014)